Lurbinectedin has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in patients who have previously received platinum-based chemotherapy and at least one other line of therapy [2]. Lurbinectedin is a selective inhibitor of oncogenic transcription and has been shown to have antitumor activity in preclinical and clinical studies [3]. According to DrugPatentWatch, Lurbinectedin is a trademark of PharmaMar, and the drug is currently in phase 3 clinical trials for the treatment of solid tumors, including lung cancer [1]. In conclusion, Lurbinectedin has been approved by the FDA for the treatment of metastatic small cell lung cancer, and it is currently being studied for the treatment of other solid tumors, including lung cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532454/